NASDAQ:CMTA - Clementia Pharmaceuticals Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
$26.35
0.00 (0.00 %)
(As of 08/23/2019 04:00 PM ET)
Today's Range
$26.35
Now: $26.35
$26.35
50-Day Range
$26.35
MA: $26.35
$26.35
52-Week Range
$8.10
Now: $26.35
$26.73
VolumeN/A
Average Volume145,059 shs
Market Capitalization$1.00 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.64
Clementia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, develops treatments for patients suffering from bone disorders and other diseases. Its lead product candidate is palovarotene, an oral small molecule for the treatment of fibrodysplasia ossificans progressive, multiple osteochondromas, dry eye disease, and other diseases is in the Phase 3 MOVE Trial. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CMTA
CUSIPN/A
Phone514-940-3600

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$5.18 per share

Profitability

Net Income$-58,130,000.00

Miscellaneous

Employees30
Market Cap$1.00 billion
Next Earnings DateN/A
OptionableNot Optionable

Receive CMTA News and Ratings via Email

Sign-up to receive the latest news and ratings for CMTA and its competitors with MarketBeat's FREE daily newsletter.


Clementia Pharmaceuticals (NASDAQ:CMTA) Frequently Asked Questions

What is Clementia Pharmaceuticals' stock symbol?

Clementia Pharmaceuticals trades on the NASDAQ under the ticker symbol "CMTA."

How were Clementia Pharmaceuticals' earnings last quarter?

Clementia Pharmaceuticals Inc (NASDAQ:CMTA) announced its earnings results on Wednesday, November, 7th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.42) by $0.04. View Clementia Pharmaceuticals' Earnings History.

What price target have analysts set for CMTA?

4 brokers have issued 1-year price targets for Clementia Pharmaceuticals' stock. Their predictions range from $26.00 to $27.00. On average, they anticipate Clementia Pharmaceuticals' share price to reach $26.50 in the next year. This suggests a possible upside of 0.6% from the stock's current price. View Analyst Price Targets for Clementia Pharmaceuticals.

What is the consensus analysts' recommendation for Clementia Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clementia Pharmaceuticals in the last year. There are currently 4 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Clementia Pharmaceuticals.

Has Clementia Pharmaceuticals been receiving favorable news coverage?

Media headlines about CMTA stock have been trending positive recently, according to InfoTrie. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Clementia Pharmaceuticals earned a news impact score of 2.5 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the stock's share price in the next several days. View News Stories for Clementia Pharmaceuticals.

Who are some of Clementia Pharmaceuticals' key competitors?

What other stocks do shareholders of Clementia Pharmaceuticals own?

Who are Clementia Pharmaceuticals' key executives?

Clementia Pharmaceuticals' management team includes the folowing people:
  • Dr. Clarissa Desjardins, Founder, Pres, CEO & Director (Age 52)
  • Dr. Donna Roy Grogan M.D., Chief Medical Officer (Age 62)
  • Mr. Jeffrey Packman, Chief Devel. Officer (Age 52)
  • Mr. Steve Forte, CFO & Corp. Sec. (Age 40)
  • Mr. Joseph Andrew Walewicz, Exec. VP of Bus. & Corp. Devel. (Age 50)

When did Clementia Pharmaceuticals IPO?

(CMTA) raised $101 million in an initial public offering on Wednesday, August 2nd 2017. The company issued 7,200,000 shares at a price of $13.00-$15.00 per share. Morgan Stanley and Leerink Partners served as the underwriters for the IPO and Wedbush Securities and BTIG were co-managers.

What is Clementia Pharmaceuticals' stock price today?

One share of CMTA stock can currently be purchased for approximately $26.35.

How big of a company is Clementia Pharmaceuticals?

Clementia Pharmaceuticals has a market capitalization of $1.00 billion. The company earns $-58,130,000.00 in net income (profit) each year or ($7.93) on an earnings per share basis. Clementia Pharmaceuticals employs 30 workers across the globe.View Additional Information About Clementia Pharmaceuticals.

What is Clementia Pharmaceuticals' official website?

The official website for Clementia Pharmaceuticals is http://www.clementiapharma.com/.

How can I contact Clementia Pharmaceuticals?

Clementia Pharmaceuticals' mailing address is 4150 ST CATHERINE STREET WEST SUITE 550, MONTREAL A8, H3Z 2Y5. The company can be reached via phone at 514-940-3600 or via email at [email protected]


MarketBeat Community Rating for Clementia Pharmaceuticals (NASDAQ CMTA)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  169 (Vote Outperform)
Underperform Votes:  199 (Vote Underperform)
Total Votes:  368
MarketBeat's community ratings are surveys of what our community members think about Clementia Pharmaceuticals and other stocks. Vote "Outperform" if you believe CMTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CMTA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/24/2019 by MarketBeat.com Staff

Featured Article: Hold Rating

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel